PMID- 28256461
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20181113
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 144
IP  - 4
DP  - 2016 Oct
TI  - Observation on frequency & clinico-pathological significance of various 
      cytogenetic risk groups in multiple myeloma: an experience from India.
PG  - 536-543
LID - 10.4103/0971-5916.200890 [doi]
AB  - BACKGROUND & OBJECTIVES: Multiple myeloma (MM) is a plasma cell malignancy 
      characterized by cytogenetic heterogeneity. In comparison with conventional 
      karyotyping, fluorescence in situ hybridization (FISH) can efficiently detect 
      various genetic changes in non-cycling plasma cells in 50-90 per cent of MM 
      cases. The present study was undertaken in MM patients to evaluate the frequency 
      and clinico-pathological significance of various cytogenetic abnormalities in the 
      Indian population. METHODS: Interphase FISH was applied on purified plasma cells 
      of 475 patients with MM using specific probes. Interphase FISH for 1q gain/1q 
      amplification was performed on a separate group of 250 newly diagnosed MM 
      patients. RESULTS: Low frequency of Delta13 [-13/del(13q)] (32%) and t(11;14) (5%) 
      was observed in our 475 patients probably due to ethnic diversity. Clustering of 
      Delta13, del(17)(p13.1) and IgH translocations in non-hyperdiploidy confirmed 
      prognostic significance of ploidy in MM. t(4;14) and del(17)(p13.1) were 
      high-risk groups due to correlation with high serum beta2-microglobulin, increased 
      plasma cells and advanced disease. Hyperdiploidy and t(14;16) were associated 
      with higher age group. In a separate group of 250 patients, 1q amplification 
      [amp(1q)] in combination with Delta13 and/or del(17p) with t(4;14) revealed 
      association with adverse clinico-laboratory features, which confirmed progressive 
      role of amp(1q) with adverse prognostic impact. Amp(1q) was clustered at 1q21 and 
      1q25 loci. INTERPRETATION & CONCLUSIONS: Based on our findings, it appears that 
      comprehensive analysis of various cytogenetic aberrations by interphase FISH is a 
      powerful strategy being adapted for risk stratification of MM.
FAU - Kadam Amare, Pratibha S
AU  - Kadam Amare PS
AD  - Department of Cancer Cytogenetics, Tata Memorial Hospital, Mumbai, India.
FAU - Jain, Hemani
AU  - Jain H
AD  - Department of Cancer Cytogenetics, Tata Memorial Hospital, Mumbai, India.
FAU - Nikalje, Shraddha
AU  - Nikalje S
AD  - Department of Cancer Cytogenetics, Tata Memorial Hospital, Mumbai, India.
FAU - Sengar, Manju
AU  - Sengar M
AD  - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
FAU - Menon, Hari
AU  - Menon H
AD  - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
FAU - Inamdar, Nitin
AU  - Inamdar N
AD  - Department of Biochemistry, Tata Memorial Hospital, Mumbai, India.
FAU - Subramanian, P G
AU  - Subramanian PG
AD  - Department of Hematopathology, Tata Memorial Hospital, Mumbai, India.
FAU - Gujral, Sumeet
AU  - Gujral S
AD  - Department of Pathology, Tata Memorial Hospital, Mumbai, India.
FAU - Shet, Tanuja
AU  - Shet T
AD  - Department of Pathology, Tata Memorial Hospital, Mumbai, India.
FAU - Epari, Sridhar
AU  - Epari S
AD  - Department of Pathology, Tata Memorial Hospital, Mumbai, India.
FAU - Nair, Reena
AU  - Nair R
AD  - Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aneuploidy
MH  - Chromosome Aberrations
MH  - Chromosome Deletion
MH  - *Cytodiagnosis
MH  - Cytogenetic Analysis
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - India
MH  - Karyotyping
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnosis/*genetics/pathology
MH  - *Prognosis
MH  - Translocation, Genetic
PMC - PMC5345299
COIS- Conflicts of Interest: None.
EDAT- 2017/03/04 06:00
MHDA- 2017/06/24 06:00
PMCR- 2016/10/01
CRDT- 2017/03/04 06:00
PHST- 2017/03/04 06:00 [entrez]
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - IndianJMedRes_2016_144_4_536_200890 [pii]
AID - IJMR-144-536 [pii]
AID - 10.4103/0971-5916.200890 [doi]
PST - ppublish
SO  - Indian J Med Res. 2016 Oct;144(4):536-543. doi: 10.4103/0971-5916.200890.